Surgical Manoeuvre for Safe Access to the Gravid Uterus

During Gynaecological surgery, a specific manoeuvre is used to safely access the gravid uterus. The bladder is reflected downwards with the peritoneum, which also displaces the distal ureters and uterine tubes. This displacement renders these structures less vulnerable to damage during the procedure. The ovarian arteries, which are branches of the aorta, are not affected by this manoeuvre. However, the uterine artery needs to be pushed down for safe ligation as the ureters typically run superior to it. The sigmoid colon is also displaced out of the operating field using this manoeuvre, reducing the risk of injury. While the ovarian arteries are unlikely to be injured during surgery as they are more lateral, the incidence of ureteric injury is 1-2% in Gynaecological surgery, with 70% of these injuries occurring during the tying off of the uterine pedicle.

In cases of recurrent vaginal candidiasis, it is recommended to consider a blood test to rule out diabetes as a potential underlying condition. Other predisposing factors such as immunosuppression, pregnancy, and antibiotic or steroid usage should also be evaluated. While HIV testing is important, a CD4+ T-cell count is not the first line investigation and HIV testing is typically done using antibody, antigen, or nucleotide testing. A full blood count may be useful to assess the patient’s general health, but it is not the most likely cause of recurrent vaginal candidiasis. HbA1c testing should be done to assess for diabetes mellitus, and a pregnancy test and HIV test may also be indicated. While a high vaginal swab can confirm the diagnosis, it will not provide information about any underlying diseases.

Vaginal candidiasis, also known as thrush, is a common condition that many women can diagnose and treat themselves. Candida albicans is responsible for about 80% of cases, while other candida species cause the remaining 20%. Although most women have no predisposing factors, certain factors such as diabetes mellitus, antibiotics, steroids, pregnancy, and HIV can increase the likelihood of developing vaginal candidiasis. Symptoms include non-offensive discharge resembling cottage cheese, vulvitis, itching, vulval erythema, fissuring, and satellite lesions. A high vaginal swab is not routinely indicated if the clinical features are consistent with candidiasis. Treatment options include local or oral therapy, with oral fluconazole 150 mg as a single dose being the first-line treatment according to NICE Clinical Knowledge Summaries. If there are vulval symptoms, a topical imidazole may be added to an oral or intravaginal antifungal. Pregnant women should only use local treatments. Recurrent vaginal candidiasis is defined as four or more episodes per year by BASHH. Compliance with previous treatment should be checked, and a high vaginal swab for microscopy and culture should be performed to confirm the diagnosis. A blood glucose test may be necessary to exclude diabetes, and differential diagnoses such as lichen sclerosus should be ruled out. An induction-maintenance regime involving oral fluconazole may be considered. Induction involves taking oral fluconazole every three days for three doses, while maintenance involves taking oral fluconazole weekly for six months.

1: If you are over 35 years old and smoke at least 15 cigarettes a day, smoking is not recommended.
2: A BMI over 35 kg/m² should be evaluated by a medical professional, but it is not considered an absolute contraindication.
3: A history of ectopic pregnancies does not affect the use of COCP.
4: It is not recommended to use COCP within 6 weeks after giving birth.
5: There is no evidence linking the use of COCP to carpal tunnel syndrome.

The decision to prescribe the combined oral contraceptive pill is now based on the UK Medical Eligibility Criteria (UKMEC), which categorizes potential contraindications and cautions on a four-point scale. UKMEC 1 indicates no restrictions for use, while UKMEC 2 suggests that the benefits outweigh the risks. UKMEC 3 indicates that the disadvantages may outweigh the advantages, and UKMEC 4 represents an unacceptable health risk. Examples of UKMEC 3 conditions include controlled hypertension, a family history of thromboembolic disease in first-degree relatives under 45 years old, and current gallbladder disease. Examples of UKMEC 4 conditions include a history of thromboembolic disease or thrombogenic mutation, breast cancer, and uncontrolled hypertension. Diabetes mellitus diagnosed over 20 years ago is classified as UKMEC 3 or 4 depending on severity. In 2016, Breastfeeding between 6 weeks and 6 months postpartum was changed from UKMEC 3 to UKMEC 2.

Teratomas, also known as dermoid cysts, are non-cancerous tumors that originate from multiple germ cell layers. These tumors can produce a variety of tissues, including skin, hair, blood, fat, bone, nails, teeth, cartilage, and thyroid tissue, due to their germ cell origin.

Mature cystic teratomas have a white shiny mass or masses projecting from the wall towards the center of the cyst. This protuberance is called the Rokitansky protuberance and is where hair, bone, teeth, and other dermal appendages usually arise from.

While ovarian malignancy is rare in young females, suspicion can be assessed using the risk of malignancy index (RMI), which takes into account serum CA-125 levels, ultrasound findings, and menopausal status.

Understanding the Different Types of Ovarian Cysts

Ovarian cysts are a common occurrence in women, and they can be classified into different types. The most common type of ovarian cyst is the physiological cyst, which includes follicular cysts and corpus luteum cysts. Follicular cysts occur when the dominant follicle fails to rupture or when a non-dominant follicle fails to undergo atresia. These cysts usually regress after a few menstrual cycles. Corpus luteum cysts, on the other hand, occur when the corpus luteum fails to break down and disappear after the menstrual cycle. These cysts may fill with blood or fluid and are more likely to cause intraperitoneal bleeding than follicular cysts.

Another type of ovarian cyst is the benign germ cell tumour, which includes dermoid cysts. Dermoid cysts are also known as mature cystic teratomas and are usually lined with epithelial tissue. They may contain skin appendages, hair, and teeth. Dermoid cysts are the most common benign ovarian tumour in women under the age of 30, and they are usually asymptomatic. However, torsion is more likely to occur with dermoid cysts than with other ovarian tumours.

Lastly, there are benign epithelial tumours, which arise from the ovarian surface epithelium. The most common benign epithelial tumour is the serous cystadenoma, which bears a resemblance to the most common type of ovarian cancer (serous carcinoma). Serous cystadenomas are bilateral in around 20% of cases. The second most common benign epithelial tumour is the mucinous cystadenoma, which is typically large and may become massive. If it ruptures, it may cause pseudomyxoma peritonei.

In conclusion, understanding the different types of ovarian cysts is important for proper diagnosis and treatment. Complex ovarian cysts should be biopsied to exclude malignancy, while benign cysts may require monitoring or surgical removal depending on their size and symptoms.

It is safe to insert a contraceptive implant after childbirth. The manufacturer of the most commonly used implant in the UK, Nexplanon®, recommends waiting at least 4 weeks postpartum for breastfeeding women. While there is no evidence of harm to the mother or baby, it is not recommended to insert an implant during pregnancy due to potential complications. It may take some time for fertility to return after pregnancy.

Implanon and Nexplanon are subdermal contraceptive implants that slowly release the progesterone hormone etonogestrel to prevent ovulation and thicken cervical mucous. Nexplanon is the newer version and has a redesigned applicator to prevent deep insertions and is radiopaque for easier location. It is highly effective with a failure rate of 0.07/100 women-years and lasts for 3 years. It does not contain estrogen, making it suitable for women with a past history of thromboembolism or migraine. It can be inserted immediately after a termination of pregnancy. However, a trained professional is needed for insertion and removal, and additional contraceptive methods are required for the first 7 days if not inserted on days 1 to 5 of a woman’s menstrual cycle.

The main disadvantage of these implants is irregular and heavy bleeding, which can be managed with a co-prescription of the combined oral contraceptive pill. Other adverse effects include headache, nausea, and breast pain. Enzyme-inducing drugs such as certain antiepileptic and rifampicin may reduce the efficacy of Nexplanon, and women should switch to a method unaffected by enzyme-inducing drugs or use additional contraception until 28 days after stopping the treatment.

There are also contraindications for using these implants, such as ischaemic heart disease/stroke, unexplained, suspicious vaginal bleeding, past breast cancer, severe liver cirrhosis, and liver cancer. Current breast cancer is a UKMEC 4 condition, which represents an unacceptable risk if the contraceptive method is used. Overall, these implants are a highly effective and long-acting form of contraception, but they require careful consideration of the potential risks and contraindications.

If a patient’s 2nd repeat cervical smear at 24 months is still positive for high-risk human papillomavirus (hrHPV), the correct course of action is to refer them for colposcopy. This is in line with the NHS cervical screening programme guidelines.

Cytological examination of the smear would not change the management of the patient and is therefore not the correct option. Regardless of cytological findings, a patient with a third hrHPV positive smear would be referred for colposcopy.

Repeating the cervical smear in 5 years is not appropriate for this patient as it is only recommended for those with negative hrHPV results.

Repeating the cervical smear after 6 months is not indicated as a test of cure for cervical intraepithelial neoplasia in this case.

Repeating the cervical smear after 12 months is also not appropriate as this is the patient’s 2nd repeat smear that is hrHPV positive. It would only be considered if it was their routine smear or 1st repeat smear that was hrHPV positive and there were no cytological abnormalities.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

Not all hormonal contraceptives are contraindicated for patients assigned female at birth undergoing testosterone therapy. The combined oral contraceptive pill, which contains oestrogen, should be avoided as it may interfere with the effects of testosterone therapy. However, the copper intrauterine device and progesterone-only pill are acceptable options as they do not have any adverse effects on testosterone therapy. The vaginal ring, which also contains oestrogen, should also be avoided.

Contraceptive and Sexual Health Guidance for Transgender and Non-Binary Individuals

The Faculty of Sexual & Reproductive Healthcare has released guidance on contraceptive choices and sexual health for transgender and non-binary individuals. The guidance emphasizes the importance of sensitive communication and offering options that consider personal preferences, co-morbidities, and current medications or therapies.

For individuals engaging in vaginal sex where there may be a risk of pregnancy and/or sexually transmitted infections, condoms and dental dams are recommended. Cervical screening and human papillomavirus vaccinations should also be offered to sexually active individuals with a uterus. Those engaging in anal sex and rimming should be advised of the risk of hepatitis A & B and offered vaccinations. Individuals at risk of HIV transmission should be advised of the availability of pre-exposure prophylaxis and post-exposure prophylaxis as required.

For patients seeking permanent contraception, a fallopian tube occlusion or a vasectomy may be the most appropriate solution and neither would be affected by hormonal therapy. Testosterone therapy does not provide protection against pregnancy, and oestrogen-containing regimes are not recommended in patients undergoing testosterone therapy. Progesterone-only contraceptives are considered safe, and the intrauterine system and injections may also suspend menstruation. Non-hormonal intrauterine devices do not interact with hormonal regimes but can exacerbate menstrual bleeding.

In patients assigned male at birth, there may be a reduction or cessation of sperm production with certain therapies, but the variability of effects means they cannot be relied upon as a method of contraception. Condoms should be recommended in those patients engaging in vaginal sex wishing to avoid the risk of pregnancy. Emergency contraception may be required in patients assigned female at birth following unprotected vaginal intercourse, and either of the available oral emergency contraceptive options may be considered. The non-hormonal intrauterine device may also be an option, but it may have unacceptable side effects in some patients.

Overall, the guidance stresses the importance of individualized care and communication in contraceptive and sexual health decisions for transgender and non-binary individuals.

When it comes to patients with suspected endometriosis, laparoscopy is considered the most reliable investigation method. This is because it enables direct visualization and biopsy of the endometrial deposits. While a CT scan may also be used to detect such deposits, it is less specific compared to MRI scans. Ultrasound can be useful in detecting endometriomas, but it is important to note that a normal scan does not necessarily rule out the possibility of endometriosis.

Understanding Endometriosis

Endometriosis is a common condition where endometrial tissue grows outside of the uterus. It affects around 10% of women of reproductive age and can cause chronic pelvic pain, painful periods, painful intercourse, and subfertility. Other symptoms may include urinary problems and painful bowel movements. Diagnosis is typically made through laparoscopy, and treatment options depend on the severity of symptoms.

First-line treatments for symptomatic relief include NSAIDs and/or paracetamol. If these do not help, hormonal treatments such as the combined oral contraceptive pill or progestogens may be tried. If symptoms persist or fertility is a priority, referral to secondary care may be necessary. Secondary treatments may include GnRH analogues or surgery. For women trying to conceive, laparoscopic excision or ablation of endometriosis plus adhesiolysis is recommended, as well as ovarian cystectomy for endometriomas.

It is important to note that there is poor correlation between laparoscopic findings and severity of symptoms, and that there is little role for investigation in primary care. If symptoms are significant, referral for a definitive diagnosis is recommended.

To diagnose PCOS, at least two out of three features must be present: oligomenorrhoea, clinical and/or biochemical signs of hyperandrogenism, and polycystic ovaries on ultrasound. In this case, the patient has oligomenorrhoea and clinical signs of hyperandrogenism, making a clinical diagnosis of PCOS likely. However, NICE guidelines recommend ruling out other potential causes of menstrual disturbance before confirming the diagnosis. BMI measurement is not necessary for diagnosis, although obesity is a common feature of PCOS. Testing for free or total testosterone levels is also not essential if clinical signs of hyperandrogenism are present.

Polycystic ovary syndrome (PCOS) is a condition that affects a significant percentage of women of reproductive age. The exact cause of PCOS is not fully understood, but it is believed to involve both high levels of luteinizing hormone and hyperinsulinemia, with some overlap with the metabolic syndrome. PCOS is characterized by a range of symptoms, including subfertility and infertility, menstrual disturbances such as oligomenorrhea and amenorrhea, hirsutism, acne, obesity, and acanthosis nigricans.

To diagnose PCOS, a range of investigations may be performed, including pelvic ultrasound to detect multiple cysts on the ovaries. Other useful baseline investigations include FSH, LH, prolactin, TSH, testosterone, and sex hormone-binding globulin (SHBG). While a raised LH:FSH ratio was once considered a classical feature of PCOS, it is no longer thought to be useful in diagnosis. Testosterone may be normal or mildly elevated, but if markedly raised, other causes should be considered. SHBG is typically normal to low in women with PCOS, and impaired glucose tolerance should also be checked.

To formally diagnose PCOS, other conditions must first be excluded. The Rotterdam criteria state that a diagnosis of PCOS can be made if at least two of the following three criteria are present: infrequent or no ovulation, clinical and/or biochemical signs of hyperandrogenism, and polycystic ovaries on ultrasound scan. Polycystic ovaries are defined as the presence of at least 12 follicles measuring 2-9 mm in diameter in one or both ovaries, and/or an increased ovarian volume of over 10 cm³.

This condition is rare, but it is more common in pregnancies that have exceeded 20 weeks of gestation.

Termination of Pregnancy in the UK

The UK’s current abortion law is based on the 1967 Abortion Act, which was amended in 1990 to reduce the upper limit for termination from 28 weeks to 24 weeks gestation. To perform an abortion, two registered medical practitioners must sign a legal document, except in emergencies where only one is needed. The procedure must be carried out by a registered medical practitioner in an NHS hospital or licensed premise.

The method used to terminate a pregnancy depends on the gestation period. For pregnancies less than nine weeks, mifepristone (an anti-progesterone) is administered, followed by prostaglandins 48 hours later to stimulate uterine contractions. For pregnancies less than 13 weeks, surgical dilation and suction of uterine contents is used. For pregnancies more than 15 weeks, surgical dilation and evacuation of uterine contents or late medical abortion (inducing ‘mini-labour’) is used.

The 1967 Abortion Act outlines the circumstances under which a person shall not be guilty of an offence under the law relating to abortion. These include if two registered medical practitioners are of the opinion, formed in good faith, that the pregnancy has not exceeded its 24th week and that the continuance of the pregnancy would involve risk, greater than if the pregnancy were terminated, of injury to the physical or mental health of the pregnant woman or any existing children of her family. The limits do not apply in cases where it is necessary to save the life of the woman, there is evidence of extreme fetal abnormality, or there is a risk of serious physical or mental injury to the woman.

The contraceptive implant primarily works by inhibiting ovulation through the slow release of progesterone hormone. While it also increases cervical mucous thickness, this is not its main mode of action. The progesterone-only pill also increases cervical mucous thickness, while the intrauterine copper device decreases sperm viability. The intrauterine system prevents implantation of the ovum by exerting local progesterone onto the uterine lining.

Understanding the Mode of Action of Contraceptives

Contraceptives are used to prevent unwanted pregnancies. They work by different mechanisms depending on the type of contraceptive used. The Faculty for Sexual and Reproductive Health (FSRH) has provided a table that outlines the mode of action of standard contraceptives and emergency contraception.

Standard contraceptives include the combined oral contraceptive pill, progesterone-only pill, injectable contraceptive, implantable contraceptive, and intrauterine contraceptive device/system. The combined oral contraceptive pill and injectable/implantable contraceptives primarily work by inhibiting ovulation, while the progesterone-only pill and some injectable/implantable contraceptives thicken cervical mucous to prevent sperm from reaching the egg. The intrauterine contraceptive device/system decreases sperm motility and survival and prevents endometrial proliferation.

Emergency contraception, which is used after unprotected sex or contraceptive failure, also works by different mechanisms. Levonorgestrel and ulipristal inhibit ovulation, while the intrauterine contraceptive device is toxic to sperm and ovum and inhibits implantation.

Understanding the mode of action of contraceptives is important in choosing the most appropriate method for an individual’s needs and preferences. It is also important to note that no contraceptive method is 100% effective, and the use of condoms can provide additional protection against sexually transmitted infections.

Premenstrual syndrome (PMS) can be helped by SSRIs, either continuously or during the luteal phase. If a patient’s symptoms are significantly impacting their day-to-day life and have not improved with first-line treatment using a combined oral contraceptive pill, antidepressant treatment with SSRIs is recommended. Co-cyprindiol, levonorgestrel-releasing intrauterine systems, mirtazapine, and the copper coil are not indicated for the management of PMS.

Understanding Premenstrual Syndrome (PMS)

Premenstrual syndrome (PMS) is a condition that affects women during the luteal phase of their menstrual cycle. It is characterized by emotional and physical symptoms that can range from mild to severe. PMS only occurs in women who have ovulatory menstrual cycles and does not occur before puberty, during pregnancy, or after menopause.

Emotional symptoms of PMS include anxiety, stress, fatigue, and mood swings. Physical symptoms may include bloating and breast pain. The severity of symptoms varies from woman to woman, and management options depend on the severity of symptoms.

Mild symptoms can be managed with lifestyle advice, such as getting enough sleep, exercising regularly, and avoiding smoking and alcohol. Specific advice includes eating regular, frequent, small, balanced meals that are rich in complex carbohydrates.

Moderate symptoms may benefit from a new-generation combined oral contraceptive pill (COCP), such as Yasmin® (drospirenone 3 mg and ethinylestradiol 0.030 mg). Severe symptoms may benefit from a selective serotonin reuptake inhibitor (SSRI), which can be taken continuously or just during the luteal phase of the menstrual cycle (for example, days 15-28, depending on the length of the cycle). Understanding PMS and its management options can help women better cope with this common condition.

Ovarian hyperstimulation syndrome can occur as a possible adverse effect of ovulation induction. The symptoms of this syndrome, such as ascites, vomiting, diarrhea, and high hematocrit, are typical. There are various medications used for ovulation induction, and the risk of ovarian hyperstimulation syndrome is higher with gonadotropin therapy than with clomiphene citrate, raloxifene, letrozole, or anastrozole. Therefore, it is probable that the patient received gonadotropin therapy.

Ovulation induction is often required for couples who have difficulty conceiving naturally due to ovulation disorders. Normal ovulation requires a balance of hormones and feedback loops between the hypothalamus, pituitary gland, and ovaries. There are three main categories of anovulation: hypogonadotropic hypogonadal anovulation, normogonadotropic normoestrogenic anovulation, and hypergonadotropic hypoestrogenic anovulation. The goal of ovulation induction is to induce mono-follicular development and subsequent ovulation to lead to a singleton pregnancy. Forms of ovulation induction include exercise and weight loss, letrozole, clomiphene citrate, and gonadotropin therapy. Ovarian hyperstimulation syndrome is a potential side effect of ovulation induction and can be life-threatening if not managed promptly.

Homologous Cells in Male and Female Reproductive Systems

The male and female reproductive systems have homologous cells that perform similar functions. Leydig cells, also known as pure Leydig cell tumors, are found in both males and females. In females, these cells are located in the ovarian hilus and secrete androgens, causing masculinization when a tumor arises. Sertoli cells, on the other hand, have a female homologue called granulosa cells, both of which are sensitive to follicle-stimulating hormone. Epithelial cells in the epididymis have a vestigial structure in females called the epoophoron, which is lined by cells similar to those found in the epididymis. Spermatocytes have female homologues in oocytes and polar bodies, while spermatogonia have female homologues in oogonia. Understanding these homologous cells can aid in the diagnosis and treatment of reproductive system disorders.

Patients with secondary dysmenorrhoea require referral to gynaecology for further investigation. This is because secondary dysmenorrhoea, which is characterized by painful cramping in the lower abdomen before or after menstruation along with new menorrhagia, suggests an underlying pathology that needs to be addressed. While mefenamic acid can help manage the pain, it is not enough to simply review the patient in two weeks without organizing referrals or investigations. The insertion of an intrauterine progesterone system may be appropriate for primary dysmenorrhoea and some cases of secondary dysmenorrhoea, but this should not be the only course of action. Additional analgesia should be considered if paracetamol is not controlling the pain. An abdominal ultrasound is not suitable for investigating pelvic organs, and a transabdominal or transvaginal pelvic ultrasound is necessary to obtain views of the uterus, ovaries, Fallopian tubes, cervix, and vagina.

Dysmenorrhoea is a condition where women experience excessive pain during their menstrual period. There are two types of dysmenorrhoea: primary and secondary. Primary dysmenorrhoea affects up to 50% of menstruating women and is not caused by any underlying pelvic pathology. It usually appears within 1-2 years of the menarche and is thought to be partially caused by excessive endometrial prostaglandin production. Symptoms include suprapubic cramping pains that may radiate to the back or down the thigh, and pain typically starts just before or within a few hours of the period starting. NSAIDs such as mefenamic acid and ibuprofen are effective in up to 80% of women, and combined oral contraceptive pills are used second line for management.

Secondary dysmenorrhoea, on the other hand, typically develops many years after the menarche and is caused by an underlying pathology. The pain usually starts 3-4 days before the onset of the period. Causes of secondary dysmenorrhoea include endometriosis, adenomyosis, pelvic inflammatory disease, intrauterine devices, and fibroids. Clinical Knowledge Summaries recommend referring all patients with secondary dysmenorrhoea to gynaecology for investigation. It is important to note that the intrauterine system (Mirena) may help dysmenorrhoea, but this only applies to normal copper coils.

Ovarian tumours are mostly epithelial in nature, comprising 90% of all cases. Serous tumours are the most common type, accounting for 50% of ovarian cancers and 20% of benign tumours. Although the 5-year survival rate is improving, it remains low at around 40% in the UK. These tumours typically affect postmenopausal women, with over 80% of cases occurring in those over 50 years old. Ovarian tumours can be benign, invasive or malignant, with different pathological subtypes. Mucinous cystadenomas are common in women aged 20-50 years and can be large and multilocular, with a risk of pseudomyxoma peritonei if they rupture. Brenner tumours are rare and often found incidentally, while teratomas are non-seminomatous germ cell tumours that may contain multiple types of tissue. Clear cell carcinomas are rare and have a worse prognosis than serous tumours, growing rapidly and being associated with endometriosis. Surgical removal is the preferred treatment for most ovarian tumours.

Medical abortions involve the use of mifepristone followed by at least one dose of prostaglandins and can be performed at any stage of pregnancy. The preferred method is oral mifepristone followed by vaginal administration of prostaglandins, such as misoprostol. This method is particularly suitable for pregnancies up to 7 weeks gestation, as it has a lower failure rate than surgical termination. The dosing schedule and location of administration may vary, with some women choosing to undergo the procedure at home rather than in a clinic. It is important to note that IM methotrexate is not used in terminations of pregnancy, but rather in the medical management of ectopic pregnancies, as well as in the treatment of certain cancers and rheumatoid conditions. Methotrexate and vaginal misoprostol is not a common combination for medical terminations, as mifepristone is typically used instead. Oral mifepristone alone is not sufficient for medical terminations, but may be used in cervical priming for surgical abortion in cases where misoprostol is contraindicated.

Termination of Pregnancy in the UK

The UK’s current abortion law is based on the 1967 Abortion Act, which was amended in 1990 to reduce the upper limit for termination from 28 weeks to 24 weeks gestation. To perform an abortion, two registered medical practitioners must sign a legal document, except in emergencies where only one is needed. The procedure must be carried out by a registered medical practitioner in an NHS hospital or licensed premise.

The method used to terminate a pregnancy depends on the gestation period. For pregnancies less than nine weeks, mifepristone (an anti-progesterone) is administered, followed by prostaglandins 48 hours later to stimulate uterine contractions. For pregnancies less than 13 weeks, surgical dilation and suction of uterine contents is used. For pregnancies more than 15 weeks, surgical dilation and evacuation of uterine contents or late medical abortion (inducing ‘mini-labour’) is used.

The 1967 Abortion Act outlines the circumstances under which a person shall not be guilty of an offence under the law relating to abortion. These include if two registered medical practitioners are of the opinion, formed in good faith, that the pregnancy has not exceeded its 24th week and that the continuance of the pregnancy would involve risk, greater than if the pregnancy were terminated, of injury to the physical or mental health of the pregnant woman or any existing children of her family. The limits do not apply in cases where it is necessary to save the life of the woman, there is evidence of extreme fetal abnormality, or there is a risk of serious physical or mental injury to the woman.

Distinguishing between common vaginal infections: Trichomoniasis, Bacterial Vaginosis, gonorrhoeae, Chlamydia, and Mycoplasma Genitalium

When a woman presents with an elevated vaginal pH, a fish-smelling, yellow vaginal discharge, and ovoid trichomonads, the diagnosis of trichomoniasis (Trichomonas vaginalis) is strongly supported. A wet saline mount or anaerobic culture can confirm the diagnosis, with culture being particularly useful in men. Treatment involves oral metronidazole for seven days or a single 2g dose, and sexual partners should also be treated to prevent re-infection.

Bacterial vaginosis is a differential diagnosis to consider, as it also presents with a fish-smelling discharge and a pH > 4.5. However, the presence of ovoid mobile parasites on wet saline mount suggests trichomoniasis as the more likely diagnosis. Bacterial vaginosis would show clue cells on wet saline mount.

gonorrhoeae and Chlamydia are sexually transmitted infections that are more likely to be seen in patients with a history of unprotected sex. However, fish-smelling discharge is not characteristic of either infection. A specimen culture of gonorrhoeae would show Gram-negative diplococci, while chlamydia would not show ovoid mobile parasites on wet saline mount.

Mycoplasma genitalium is another potential sexually transmitted infection that can cause urethritis, discharge, cervicitis, or endometritis in women. However, the wet saline mount results suggest that this is not the diagnosis, and fish-smelling discharge is not characteristic of this infection.

In summary, a combination of clinical presentation, wet saline mount, and culture can help distinguish between common vaginal infections such as trichomoniasis, bacterial vaginosis, gonorrhoeae, chlamydia, and mycoplasma genitalium.

Contraception for Women with Epilepsy

Women with epilepsy need to consider several factors when choosing a contraceptive method. Firstly, they need to consider how the contraceptive may affect the effectiveness of their anti-epileptic medication. Secondly, they need to consider how their anti-epileptic medication may affect the effectiveness of the contraceptive. Lastly, they need to consider the potential teratogenic effects of their anti-epileptic medication if they become pregnant.

To address these concerns, the Faculty of Sexual & Reproductive Healthcare (FSRH) recommends that women with epilepsy consistently use condoms in addition to other forms of contraception. For women taking certain anti-epileptic medications such as phenytoin, carbamazepine, barbiturates, primidone, topiramate, and oxcarbazepine, the FSRH recommends the use of the COCP and POP as UKMEC 3, the implant as UKMEC 2, and the Depo-Provera, IUD, and IUS as UKMEC 1.

For women taking lamotrigine, the FSRH recommends the use of the COCP as UKMEC 3 and the POP, implant, Depo-Provera, IUD, and IUS as UKMEC 1. If a COCP is chosen, it should contain a minimum of 30 µg of ethinylestradiol. By considering these recommendations, women with epilepsy can make informed decisions about their contraceptive options and ensure the safety and effectiveness of their chosen method.

Management of Menopausal Symptoms: Lifestyle Changes and Medication Options

Menopausal symptoms, such as hot flashes and mood disturbance, can significantly impact a woman’s quality of life. The first step in managing these symptoms should involve lifestyle changes, such as reducing caffeine and alcohol intake, regular exercise, and weight loss. If symptoms persist or worsen, medication options such as hormone replacement therapy (HRT) or selective serotonin reuptake inhibitors (SSRIs) can be considered.

Cognitive behavioral therapy (CBT) is also an option for women experiencing mood disturbance, anxiety, or depression. However, it is important to note that SSRIs should only be used for severe symptoms that have not improved with lifestyle changes. When starting SSRIs, patients should be reviewed after two weeks and then again after three months if symptoms have improved.

While over-the-counter herbal products like St John’s wort, isoflavones, and black cohosh have been associated with symptom improvement, their safety and efficacy are unknown. It is not recommended for doctors to suggest these products, and patients should be warned of potential risks and interactions with other medications.

Overall, the management of menopausal symptoms should involve a combination of lifestyle changes and medication options, with regular review of symptoms to ensure the best possible outcome for the patient.

Understanding Uterine Fibroids

Uterine fibroids are non-cancerous growths that develop in the uterus. They are more common in black women and are thought to occur in around 20% of white women in their later reproductive years. Fibroids are usually asymptomatic, but they can cause menorrhagia, which can lead to iron-deficiency anaemia. Other symptoms include lower abdominal pain, bloating, and urinary symptoms. Fibroids may also cause subfertility.

Diagnosis is usually made through transvaginal ultrasound. Asymptomatic fibroids do not require treatment, but periodic monitoring is recommended. Menorrhagia secondary to fibroids can be managed with various treatments, including the levonorgestrel intrauterine system, NSAIDs, tranexamic acid, and hormonal therapies.

Medical treatment to shrink or remove fibroids may include GnRH agonists or ulipristal acetate, although the latter is not currently recommended due to concerns about liver toxicity. Surgical options include myomectomy, hysteroscopic endometrial ablation, hysterectomy, and uterine artery embolization.

Fibroids generally regress after menopause, but complications such as subfertility and iron-deficiency anaemia can occur. Red degeneration, which is haemorrhage into the tumour, is a common complication during pregnancy.

Injectable progesterone contraceptives are not recommended for individuals with current breast cancer.

This is considered an absolute contraindication (UKMEC 4) for prescribing injectable progesterone contraceptives. It is also an absolute contraindication for most other forms of contraception, except for the non-hormonal copper intrauterine device.

Current deep vein thrombosis is a UKMEC 2 contraindication for injectable progesterone, while it is a UKMEC 4 contraindication for the combined oral contraceptive pill. Multiple cardiovascular risk factors are a UKMEC 3 contraindication, which is not absolute, but the risks are generally considered to outweigh the benefits.

Smoking 30 cigarettes per day is only a UKMEC 1 contraindication for injectable progesterone contraception. However, considering the individual’s age, it would be a UKMEC 4 contraindication for the combined oral contraceptive pill.

High BMI is a UKMEC 1 contraindication for most forms of contraception, including injectable progesterone. However, it would be a UKMEC 4 contraindication for the combined pill.

Injectable Contraceptives: Depo Provera

Injectable contraceptives are a popular form of birth control in the UK, with Depo Provera being the main option available. This contraceptive contains 150 mg of medroxyprogesterone acetate and is administered via intramuscular injection every 12 weeks. It can be given up to 14 weeks after the last dose without the need for extra precautions. The primary method of action is by inhibiting ovulation, while secondary effects include cervical mucous thickening and endometrial thinning.

However, there are some disadvantages to using Depo Provera. Once the injection is given, it cannot be reversed, and there may be a delayed return to fertility of up to 12 months. Adverse effects may include irregular bleeding and weight gain, and there is a potential increased risk of osteoporosis. It should only be used in adolescents if no other method of contraception is suitable.

It is important to note that there are contraindications to using Depo Provera, such as current breast cancer (UKMEC 4) or past breast cancer (UKMEC 3). While Noristerat is another injectable contraceptive licensed in the UK, it is rarely used in clinical practice and is given every 8 weeks. Overall, injectable contraceptives can be an effective form of birth control, but it is important to weigh the potential risks and benefits before deciding on this method.

Prolapse refers to the descent of pelvic organs into the vagina, which can be categorized into different degrees. First-degree prolapse involves the descent of the uterus and cervix, but they do not reach the vaginal opening. Second-degree prolapse is when the cervix descends to the level of the introitus. Third-degree prolapse is the protrusion of the cervix and uterus outside of the vagina. Fourth-degree prolapse is the complete prolapse of the cervix, uterus, and vaginal wall, which can cause bleeding due to cervix ulceration. Vault prolapse is the prolapse of the top of the vagina down the vaginal canal, often occurring after a hysterectomy due to weakness of the upper vagina. The causes of urogenital prolapse are multifactorial and can include factors such as childbirth, menopause, chronic cough, obesity, constipation, and suprapubic surgery for urinary continence.

In cases where delayed placental delivery is observed in patients with placenta accreta, hysterectomy is the recommended treatment. This patient has a history of previous caesarean-section and pelvic inflammatory disease, indicating a likely placenta accreta, which was also diagnosed antenatally on ultrasound. The optimal management approach involves leaving the placenta in-situ and performing a hysterectomy to avoid potential haemorrhage from attempts to actively remove the placenta. While medical management with oxytocin and ergometrine may help manage post-partum haemorrhage, it is not a definitive treatment option. Cord traction is also unlikely to be effective as the placenta is abnormally implanted into the uterine wall. Waiting another 30 minutes is not advisable due to the risk of further bleeding.

Understanding Placenta Accreta

Placenta accreta is a condition where the placenta attaches to the myometrium instead of the decidua basalis, which can lead to postpartum hemorrhage. This condition is caused by a defective decidua basalis. There are three types of placenta accreta, which are categorized based on the degree of invasion. The first type is accreta, where the chorionic villi attach to the myometrium. The second type is increta, where the chorionic villi invade into the myometrium. The third type is percreta, where the chorionic villi invade through the perimetrium.

There are certain risk factors that increase the likelihood of developing placenta accreta, such as having a previous caesarean section or placenta previa. It is important for healthcare providers to be aware of these risk factors and monitor patients closely during pregnancy and delivery. Early detection and management of placenta accreta can help prevent complications and ensure the best possible outcome for both the mother and baby.

Endometrial cancer is more likely to occur in women who have never given birth. One of the warning signs of endometrial cancer is bleeding after menopause. Chronic obstructive pulmonary disease is not a known risk factor for endometrial cancer, but conditions such as type 2 diabetes mellitus and polycystic ovary syndrome are. While late menopause can increase the risk of endometrial cancer, this patient experienced menopause at around age 50, which is slightly earlier than average. Smoking is not a risk factor for endometrial cancer, but it is associated with an increased risk of other types of cancer such as cervical, vulval, and breast cancer. On the other hand, taking the combined oral contraceptive pill can lower the risk of endometrial cancer, but it may increase the risk of breast and cervical cancer.

Endometrial cancer is a type of cancer that is commonly found in women who have gone through menopause, but it can also occur in around 25% of cases before menopause. The prognosis for this type of cancer is usually good due to early detection. There are several risk factors associated with endometrial cancer, including obesity, nulliparity, early menarche, late menopause, unopposed estrogen, diabetes mellitus, tamoxifen, polycystic ovarian syndrome, and hereditary non-polyposis colorectal carcinoma. Postmenopausal bleeding is the most common symptom of endometrial cancer, which is usually slight and intermittent initially before becoming more heavy. Pain is not common and typically signifies extensive disease, while vaginal discharge is unusual.

When investigating endometrial cancer, women who are 55 years or older and present with postmenopausal bleeding should be referred using the suspected cancer pathway. The first-line investigation is trans-vaginal ultrasound, which has a high negative predictive value for a normal endometrial thickness (< 4 mm). Hysteroscopy with endometrial biopsy is also commonly used for investigation. The management of localized disease involves total abdominal hysterectomy with bilateral salpingo-oophorectomy, while patients with high-risk disease may have postoperative radiotherapy. progesterone therapy is sometimes used in frail elderly women who are not considered suitable for surgery. It is important to note that the combined oral contraceptive pill and smoking are protective against endometrial cancer.

It is a common scenario for surgical patients to face an increased risk of venous thromboembolism when they are on the pill and undergoing surgery, particularly abdominal or lower limb surgery. Therefore, it is necessary to discontinue the pill.

However, stopping the pill too early would increase the risk of pregnancy, and restarting it too soon after surgery would still pose a risk due to the surgery’s effects on coagulation. Ceasing the pill on the day of surgery would not eliminate the risk of clotting either.

The best course of action is to stop the pill four weeks before surgery to allow for a return to normal coagulation levels. Then, restarting it two weeks after surgery would allow the procoagulant effects of surgery to subside.

The decision to prescribe the combined oral contraceptive pill is now based on the UK Medical Eligibility Criteria (UKMEC), which categorizes potential contraindications and cautions on a four-point scale. UKMEC 1 indicates no restrictions for use, while UKMEC 2 suggests that the benefits outweigh the risks. UKMEC 3 indicates that the disadvantages may outweigh the advantages, and UKMEC 4 represents an unacceptable health risk. Examples of UKMEC 3 conditions include controlled hypertension, a family history of thromboembolic disease in first-degree relatives under 45 years old, and current gallbladder disease. Examples of UKMEC 4 conditions include a history of thromboembolic disease or thrombogenic mutation, breast cancer, and uncontrolled hypertension. Diabetes mellitus diagnosed over 20 years ago is classified as UKMEC 3 or 4 depending on severity. In 2016, Breastfeeding between 6 weeks and 6 months postpartum was changed from UKMEC 3 to UKMEC 2.

Breastfeeding mothers should steer clear of aspirin

Breastfeeding mothers are advised against taking aspirin, especially in high doses for pain relief. This is because aspirin has been linked to Reye’s syndrome, a condition that can result in liver and brain harm.

Breastfeeding has some contraindications that are important to know, especially when it comes to drugs. Antibiotics like penicillins, cephalosporins, and trimethoprim are safe for breastfeeding mothers, as are endocrine drugs like glucocorticoids (in low doses) and levothyroxine. Epilepsy drugs like sodium valproate and carbamazepine, asthma drugs like salbutamol and theophyllines, and hypertension drugs like beta-blockers and hydralazine are also safe. Anticoagulants like warfarin and heparin, as well as digoxin, are also safe. However, some drugs should be avoided, such as antibiotics like ciprofloxacin, tetracycline, chloramphenicol, and sulphonamides, psychiatric drugs like lithium and benzodiazepines, aspirin, carbimazole, methotrexate, sulfonylureas, cytotoxic drugs, and amiodarone. Other contraindications include galactosaemia and viral infections, although the latter is controversial in the developing world due to the increased risk of infant mortality and morbidity associated with bottle feeding.

If a patient presents with symptoms highly suggestive of vaginal candidiasis, a high vaginal swab is not necessary for diagnosis and treatment can be initiated with a single oral dose of fluconazole. Symptoms of vaginal candidiasis include vulval soreness, itching, and thick, white vaginal discharge. Prescribing oral metronidazole as a single dose or taking a high vaginal swab would be incorrect as they are used to treat Trichomonas vaginalis infections or bacterial vaginosis, respectively.

Vaginal candidiasis, also known as thrush, is a common condition that many women can diagnose and treat themselves. Candida albicans is responsible for about 80% of cases, while other candida species cause the remaining 20%. Although most women have no predisposing factors, certain factors such as diabetes mellitus, antibiotics, steroids, pregnancy, and HIV can increase the likelihood of developing vaginal candidiasis. Symptoms include non-offensive discharge resembling cottage cheese, vulvitis, itching, vulval erythema, fissuring, and satellite lesions. A high vaginal swab is not routinely indicated if the clinical features are consistent with candidiasis. Treatment options include local or oral therapy, with oral fluconazole 150 mg as a single dose being the first-line treatment according to NICE Clinical Knowledge Summaries. If there are vulval symptoms, a topical imidazole may be added to an oral or intravaginal antifungal. Pregnant women should only use local treatments. Recurrent vaginal candidiasis is defined as four or more episodes per year by BASHH. Compliance with previous treatment should be checked, and a high vaginal swab for microscopy and culture should be performed to confirm the diagnosis. A blood glucose test may be necessary to exclude diabetes, and differential diagnoses such as lichen sclerosus should be ruled out. An induction-maintenance regime involving oral fluconazole may be considered. Induction involves taking oral fluconazole every three days for three doses, while maintenance involves taking oral fluconazole weekly for six months.

The presence of fibroids in the patient’s uterus is indicated by her symptoms of intermenstrual bleeding, pelvic pain, and menorrhagia, as well as her age. While GnRH agonists may temporarily reduce the size of the fibroids, they are not a long-term solution.

Understanding Uterine Fibroids

Uterine fibroids are non-cancerous growths that develop in the uterus. They are more common in black women and are thought to occur in around 20% of white women in their later reproductive years. Fibroids are usually asymptomatic, but they can cause menorrhagia, which can lead to iron-deficiency anaemia. Other symptoms include lower abdominal pain, bloating, and urinary symptoms. Fibroids may also cause subfertility.

Diagnosis is usually made through transvaginal ultrasound. Asymptomatic fibroids do not require treatment, but periodic monitoring is recommended. Menorrhagia secondary to fibroids can be managed with various treatments, including the levonorgestrel intrauterine system, NSAIDs, tranexamic acid, and hormonal therapies.

Medical treatment to shrink or remove fibroids may include GnRH agonists or ulipristal acetate, although the latter is not currently recommended due to concerns about liver toxicity. Surgical options include myomectomy, hysteroscopic endometrial ablation, hysterectomy, and uterine artery embolization.

Fibroids generally regress after menopause, but complications such as subfertility and iron-deficiency anaemia can occur. Red degeneration, which is haemorrhage into the tumour, is a common complication during pregnancy.

When it comes to patients with suspected endometriosis, laparoscopy is considered the most reliable investigation method.

Understanding Endometriosis

Endometriosis is a common condition where endometrial tissue grows outside of the uterus. It affects around 10% of women of reproductive age and can cause chronic pelvic pain, painful periods, painful intercourse, and subfertility. Other symptoms may include urinary problems and painful bowel movements. Diagnosis is typically made through laparoscopy, and treatment options depend on the severity of symptoms.

First-line treatments for symptomatic relief include NSAIDs and/or paracetamol. If these do not help, hormonal treatments such as the combined oral contraceptive pill or progestogens may be tried. If symptoms persist or fertility is a priority, referral to secondary care may be necessary. Secondary treatments may include GnRH analogues or surgery. For women trying to conceive, laparoscopic excision or ablation of endometriosis plus adhesiolysis is recommended, as well as ovarian cystectomy for endometriomas.

It is important to note that there is poor correlation between laparoscopic findings and severity of symptoms, and that there is little role for investigation in primary care. If symptoms are significant, referral for a definitive diagnosis is recommended.